Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals develops and commercializes oral small-molecule therapies for rare diseases, with a focus on the kallikrein-kinin system. Its FDA-approved product EKTERLY (sebetralstat) is an oral plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema, and company updates often center on launch activity, product revenue, and use of oral on-demand therapy in HAE.
KalVista news also covers clinical and scientific updates for sebetralstat, including pediatric HAE work through the KONFIDENT-KID trial, medical-conference presentations, financial results, inducement equity grants, governance matters, capital-structure disclosures, and material agreements.
KalVista Pharmaceuticals (Nasdaq: KALV) presented new real-world data on injectable on-demand treatment burden in children aged 2–11 with hereditary angioedema (HAE). Findings show high use of off-label injectables, substantial emergency room visits, significant child and caregiver anxiety, and frequent treatment delays. KalVista is running the KONFIDENT-KID pediatric HAE trial and plans to submit a sebetralstat NDA for ages 2–11 in Q3 2026.
Chiesi Group agreed to acquire KalVista Pharmaceuticals (Nasdaq: KALV) for $27.00 per share in cash, implying an equity value of approximately $1.9bn. The tender-offer transaction, unanimously approved by both boards, is expected to close in Q3 2026 pending customary closing conditions and regulatory approvals. Chiesi will assume responsibility for EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema, which launched in the U.S. in July 2025 and reached $49M in 2025 sales. Chiesi says sebetralstat is expected to contribute to its 2030 €6bn revenue target.
Alpha Cognition (Nasdaq: ACOG) appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of finance, strategy, and operations experience, including CFO roles at Radius Health and 9 Meters, and Biogen P&L responsibility for >$1 billion across 30 countries. The company said her expertise will support the commercial launch of ZUNVEYL and ongoing development of its sublingual program. Alpha Cognition also announced that founding director Len Mertz will not seek re-election after guiding the company to an FDA-approved product.
KalVista Pharmaceuticals (Nasdaq: KALV) will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 10:15 a.m. EST in a fireside chat.
A live audio webcast will be available on the company’s Investor website, with an archived replay posted about two hours after the event.
KalVista Pharmaceuticals (Nasdaq: KALV) granted inducement stock options to five newly hired employees totaling 66,375 shares on April 1, 2026. Options exercise price will equal the first reported closing price after the grant date. One-fourth vests after one year; remaining vest monthly over three years. Each option has a 10-year term and is governed by the company’s Inducement Equity Incentive Plan and individual option agreements, and the grants comply with Nasdaq Listing Rule 5635(c)(4).
KalVista (Nasdaq: KALV) reported positive interim Phase 3 KONFIDENT-KID results for EKTERLY (sebetralstat) in children aged 2-11.
Among 172 treated HAE attacks in 33 pediatric participants (data cut Dec 15, 2025): mean 0.7 attacks treated/patient/month, median time to treatment 25 minutes (67% within 1 hour), 88.9% mild/moderate. In the 150 mg cohort median symptom relief was 1.5 hours and complete resolution 12 hours. Sebetralstat was well tolerated with no serious or treatment-related adverse events and no swallowing issues. Enrollment finished one year early; KalVista expects a US NDA in Q3 2026 and a 2027 launch if approved.
KalVista Pharmaceuticals (Nasdaq: KALV) reported results for the eight months ended December 31, 2025, following a fiscal-year change. EKTERLY generated $49.1 million global net product revenue since launch and recorded 1,702 US patient start forms through February 28, 2026 (about 20% of the US patient population).
Key clinical progress includes completed pediatric Phase 3 enrollment and planned US NDA filing in Q3 2026; cash and marketable securities were approximately $300.2 million at year-end.
KalVista Pharmaceuticals (Nasdaq: KALV) will present five abstracts, including a late-breaking oral poster, at the 2026 Global Angioedema Leadership Conference in Madrid from March 26–29, 2026.
The late-breaking oral is an interim analysis of KONFIDENT-KID evaluating sebetralstat for on-demand treatment of hereditary angioedema attacks in children aged 2–11, plus four KONFIDENT-S and patient-survey posters.
KalVista Pharmaceuticals (Nasdaq: KALV) will host a conference call and webcast on March 25, 2026 at 8:30 a.m. ET to review eight months fiscal year 2025 financial results and provide a corporate update. The live webcast and an archived replay will be available on the company investor website.
KalVista Pharmaceuticals (NASDAQ: KALV) reported inducement option grants for a newly hired employee: an aggregate of 6,750 options granted on March 1, 2026, under Nasdaq Listing Rule 5635(c)(4). Exercise price will equal the first reported closing price after the grant. Options vest 25% after one year, then monthly over three years, have a 10-year term, and are governed by the company's Inducement Equity Incentive Plan and a stock option agreement.